297 related articles for article (PubMed ID: 35529597)
1. Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation-Adjusting the Odds?
Seehofer D; Petrowsky H; Schneeberger S; Vibert E; Ricke J; Sapisochin G; Nault JC; Berg T
Transpl Int; 2022; 35():10333. PubMed ID: 35529597
[No Abstract] [Full Text] [Related]
2. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
3. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation.
Sharr WW; Chan SC; Lo CM
Transplantation; 2014 Apr; 97 Suppl 8():S10-7. PubMed ID: 24849822
[TBL] [Abstract][Full Text] [Related]
4. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.
Degroote H; Piñero F; Costentin C; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas AL; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Di Benedetto F; Duque SH; Salame E; Cillo U; Gadano A; Vanlemmens C; Fagiuoli S; Rubinstein F; Burra P; Cherqui D; Silva M; Van Vlierberghe H; Duvoux C;
JHEP Rep; 2021 Oct; 3(5):100331. PubMed ID: 34485882
[TBL] [Abstract][Full Text] [Related]
5. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
[TBL] [Abstract][Full Text] [Related]
6. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
[TBL] [Abstract][Full Text] [Related]
7. Comparison between living donor liver transplantation recipients who met the Milan and UCSF criteria after successful downstaging therapies.
Lei J; Yan L
J Gastrointest Surg; 2012 Nov; 16(11):2120-5. PubMed ID: 22948843
[TBL] [Abstract][Full Text] [Related]
8. Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria.
Bhangui P; Saigal S; Gautam D; Piplani T; Choudhary N; Chaudhary R; Yadav S; Thiagarajan S; Rastogi A; Saraf N; Nundy S; Soin AS
Liver Transpl; 2021 Feb; 27(2):209-221. PubMed ID: 33253492
[TBL] [Abstract][Full Text] [Related]
9. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
[TBL] [Abstract][Full Text] [Related]
10. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
[TBL] [Abstract][Full Text] [Related]
11. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis.
Parikh ND; Waljee AK; Singal AG
Liver Transpl; 2015 Sep; 21(9):1142-52. PubMed ID: 25981135
[TBL] [Abstract][Full Text] [Related]
12. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
14. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
Tabrizian P; Holzner ML; Mehta N; Halazun K; Agopian VG; Yao F; Busuttil RW; Roberts J; Emond JC; Samstein B; Brown RS; Najjar M; Chapman WC; Doyle MM; Florman SS; Schwartz ME; Llovet JM
JAMA Surg; 2022 Sep; 157(9):779-788. PubMed ID: 35857294
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
16. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
17. Hangzhou criteria as downstaging criteria in hepatocellular carcinoma before liver transplantation: A multicenter study from China.
Zhan QF; Ling SB; Deng YN; Shan QN; Ye QW; Xu SJ; Jiang GJ; Lu D; Wei XY; Zhuang L; Zhang W; Shen T; Cen BN; Xie HY; Liu JM; Wu J; Zheng SS; Yang Y; Xu X
Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):349-357. PubMed ID: 32622826
[TBL] [Abstract][Full Text] [Related]
18. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions.
Chapman WC; Garcia-Aroz S; Vachharajani N; Fowler K; Saad N; Lin Y; Wellen J; Tan B; Khan AS; Doyle MB
J Am Coll Surg; 2017 Apr; 224(4):610-621. PubMed ID: 28069527
[TBL] [Abstract][Full Text] [Related]
19. Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Kim HD; Shim JH; Kim GA; Shin YM; Yu E; Lee SG; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
J Hepatol; 2015 May; 62(5):1076-84. PubMed ID: 25529626
[TBL] [Abstract][Full Text] [Related]
20. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
Yao FY; Mehta N; Flemming J; Dodge J; Hameed B; Fix O; Hirose R; Fidelman N; Kerlan RK; Roberts JP
Hepatology; 2015 Jun; 61(6):1968-77. PubMed ID: 25689978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
